BRPI0408767A - inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv - Google Patents
inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hivInfo
- Publication number
- BRPI0408767A BRPI0408767A BRPI0408767-4A BRPI0408767A BRPI0408767A BR PI0408767 A BRPI0408767 A BR PI0408767A BR PI0408767 A BRPI0408767 A BR PI0408767A BR PI0408767 A BRPI0408767 A BR PI0408767A
- Authority
- BR
- Brazil
- Prior art keywords
- hiv
- treatment
- reverse transcriptase
- formula
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/13—Oxygen atoms
Abstract
"INIBIDORES DA TRANSCRIPTASE REVERSA NãO-NUCLEOSìDEOS I PARA O TRATAMENTO DE DOENçAS MEDIADAS PELO HIV". A presente invenção refere-se a novos compostos heterocíclicos de fórmula (I), em que R¬ 1¬-R¬ 4¬, X¬ 1¬ e X¬ 2¬ são como definidos no sumário e sais e solvatos farmaceuticamente aceitáveis destes, métodos para inibir ou modular a transcriptase reversa do Vírus da Imunodeficiência Humana (HIV) com compostos de fórmula (I), composições farmacêuticas contendo a fórmula I misturadas com pelo menos um solvente, veículo ou excipiente e processos para se preparar os compostos de fórmula I. O compostos são úteis para o tratamento de distúrbios, em que o HIV e os vírus geneticamente relacionados estão envolvidos.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR122016023941-1A BR122016023941B1 (pt) | 2003-03-24 | 2004-03-22 | Inibidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso e composição farmacêutica |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45713003P | 2003-03-24 | 2003-03-24 | |
US60/457,130 | 2003-03-24 | ||
PCT/EP2004/002995 WO2004085411A1 (en) | 2003-03-24 | 2004-03-22 | Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0408767A true BRPI0408767A (pt) | 2006-03-28 |
BRPI0408767B1 BRPI0408767B1 (pt) | 2017-10-31 |
BRPI0408767B8 BRPI0408767B8 (pt) | 2021-05-25 |
Family
ID=33098199
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122016023941-1A BR122016023941B1 (pt) | 2003-03-24 | 2004-03-22 | Inibidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso e composição farmacêutica |
BRPI0408767A BRPI0408767B8 (pt) | 2003-03-24 | 2004-03-22 | inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122016023941-1A BR122016023941B1 (pt) | 2003-03-24 | 2004-03-22 | Inibidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso e composição farmacêutica |
Country Status (20)
Country | Link |
---|---|
US (2) | US7208509B2 (pt) |
EP (1) | EP1608633B1 (pt) |
JP (1) | JP4708329B2 (pt) |
KR (1) | KR101122456B1 (pt) |
CN (1) | CN100588650C (pt) |
AR (1) | AR043673A1 (pt) |
AU (1) | AU2004224153B2 (pt) |
BR (2) | BR122016023941B1 (pt) |
CA (1) | CA2518437C (pt) |
CL (1) | CL2004000590A1 (pt) |
CO (1) | CO5601029A2 (pt) |
ES (1) | ES2574580T3 (pt) |
HR (1) | HRP20050830A2 (pt) |
IL (1) | IL170343A (pt) |
MX (1) | MXPA05010210A (pt) |
NO (1) | NO334095B1 (pt) |
NZ (1) | NZ541829A (pt) |
RU (1) | RU2342367C2 (pt) |
TW (1) | TW200505441A (pt) |
WO (1) | WO2004085411A1 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602005027677D1 (de) * | 2004-04-01 | 2011-06-09 | Aventis Pharma Inc | 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung |
RU2394028C2 (ru) * | 2004-07-27 | 2010-07-10 | Ф.Хоффманн-Ля Рош Аг | Производные бензилтриазолона в качестве ненуклеозидных ингибиторов обратной транскриптазы |
US8293778B2 (en) | 2004-07-27 | 2012-10-23 | Roche Palo Alto Llc | Heterocyclic antiviral compounds |
JP2008534456A (ja) * | 2005-03-24 | 2008-08-28 | エフ.ホフマン−ラ ロシュ アーゲー | ヘテロ環式逆転写酵素インヒビターとしての1,2,4−トリアゾール−5−オン化合物 |
AR057455A1 (es) | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
AU2006298853A1 (en) * | 2005-09-30 | 2007-04-12 | F. Hoffmann-La Roche Ag | NNRT inhibitors |
KR20080056220A (ko) | 2005-10-19 | 2008-06-20 | 에프. 호프만-라 로슈 아게 | 페닐-아세트아마이드 nnrt 저해제 |
US20080293775A1 (en) * | 2005-12-15 | 2008-11-27 | Astrazeneca Ab | Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease |
TWI411613B (zh) | 2006-07-07 | 2013-10-11 | Gilead Sciences Inc | 用於改善被細胞色素p450單氧合酶所代謝之治療劑的藥物動力性質之調節劑 |
CL2007002105A1 (es) * | 2006-07-21 | 2008-02-22 | Hoffmann La Roche | Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u |
AU2007286345B2 (en) | 2006-08-16 | 2012-03-08 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
TW200831085A (en) * | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
MX2009008935A (es) * | 2007-02-23 | 2009-11-02 | Gilead Sciences Inc | Moduladores de las propiedades farmacocineticas de productos terapeuticos. |
AU2008235549A1 (en) * | 2007-04-09 | 2008-10-16 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
MX2009012706A (es) * | 2007-05-30 | 2009-12-08 | Hoffmann La Roche | Proceso para preparar triazolonas. |
MX2009012704A (es) | 2007-05-30 | 2009-12-08 | Hoffmann La Roche | Inhibidores de transcriptasa inversa de no nucleosidos. |
WO2008157273A1 (en) * | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Chemical compounds |
WO2008157330A1 (en) * | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Chemical compounds |
BRPI0813404A2 (pt) * | 2007-06-22 | 2014-12-30 | Hoffmann La Roche | Derivados de uréia e carbamato como inibidores de transcriptase reversa de não-nucleosídeo |
US8492415B2 (en) * | 2007-07-03 | 2013-07-23 | Yale University | Azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiviral therapy (HIV) |
MX2010006397A (es) * | 2007-12-21 | 2010-07-05 | Hoffmann La Roche | Compuestos heterociclicos antivirales. |
EA024804B1 (ru) * | 2010-03-30 | 2016-10-31 | Мерк Кэнэда Инк. | Ненуклеозидные ингибиторы обратной транскриптазы, композиции, их содержащие, и их применение |
CU23896B1 (es) * | 2010-04-01 | 2013-05-31 | Ct De Ingeniería Genética Y Biotecnología | Método para inhibir la replicación del vih en células de mamíferos |
JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
CN104230929B (zh) * | 2013-06-19 | 2015-11-18 | 华东师范大学 | 一种非核苷类hiv-1反转录酶抑制剂 |
EP3125894B1 (en) | 2014-04-01 | 2020-09-09 | Merck Sharp & Dohme Corp. | Prodrugs of hiv reverse transcriptase inhibitors |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3274185A (en) | 1963-10-08 | 1966-09-20 | S E Massengill Company | Phthalazine derivatives |
US3813384A (en) | 1972-01-17 | 1974-05-28 | Asta Werke Ag Chem Fab | Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof |
US5436252A (en) | 1986-12-19 | 1995-07-25 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders |
JP2593084B2 (ja) | 1986-12-19 | 1997-03-19 | メレルダウファーマスーティカルズ インコーポレーテッド | 5−アリールー3h−1,2,4−トリアゾールー3−オン類の神経変性障害の処置への用途 |
PH24094A (en) | 1986-12-19 | 1990-03-05 | Merrell Dow Pharma | 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants |
US4942236A (en) | 1987-09-30 | 1990-07-17 | American Home Products Corporation | 2-aryl substituted pyridyl-containing phenyl sulfonamido compounds as antiallergic and antiinflammatory agents |
US5103014A (en) | 1987-09-30 | 1992-04-07 | American Home Products Corporation | Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives |
US4826990A (en) | 1987-09-30 | 1989-05-02 | American Home Products Corporation | 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents |
US4966909A (en) | 1989-12-20 | 1990-10-30 | Merrell Dow Pharmaceuticals | 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants |
US5331002A (en) | 1990-04-19 | 1994-07-19 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers |
US5922751A (en) | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
US5641796A (en) | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
WO1997040017A2 (en) | 1996-04-19 | 1997-10-30 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
TW467902B (en) | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
GB2384776C (en) * | 2000-10-30 | 2006-02-03 | Kudos Pharm Ltd | Phthalazinone derivatives |
UA82048C2 (uk) | 2000-11-10 | 2008-03-11 | Эли Лилли Энд Компани | Агоністи альфа-рецепторів, активованих проліфератором пероксисом |
JP2002275165A (ja) * | 2001-01-12 | 2002-09-25 | Sumitomo Pharmaceut Co Ltd | トリアゾール誘導体 |
-
2004
- 2004-03-18 TW TW093107292A patent/TW200505441A/zh unknown
- 2004-03-22 JP JP2006504792A patent/JP4708329B2/ja not_active Expired - Lifetime
- 2004-03-22 AU AU2004224153A patent/AU2004224153B2/en not_active Expired
- 2004-03-22 RU RU2005132632/04A patent/RU2342367C2/ru active
- 2004-03-22 MX MXPA05010210A patent/MXPA05010210A/es active IP Right Grant
- 2004-03-22 BR BR122016023941-1A patent/BR122016023941B1/pt active IP Right Grant
- 2004-03-22 CL CL200400590A patent/CL2004000590A1/es unknown
- 2004-03-22 CN CN200480006480A patent/CN100588650C/zh not_active Expired - Lifetime
- 2004-03-22 KR KR1020057017771A patent/KR101122456B1/ko active IP Right Grant
- 2004-03-22 BR BRPI0408767A patent/BRPI0408767B8/pt active IP Right Grant
- 2004-03-22 NZ NZ541829A patent/NZ541829A/en unknown
- 2004-03-22 WO PCT/EP2004/002995 patent/WO2004085411A1/en active Application Filing
- 2004-03-22 EP EP04722259.1A patent/EP1608633B1/en not_active Expired - Lifetime
- 2004-03-22 AR ARP040100937A patent/AR043673A1/es not_active Application Discontinuation
- 2004-03-22 ES ES04722259.1T patent/ES2574580T3/es not_active Expired - Lifetime
- 2004-03-22 CA CA2518437A patent/CA2518437C/en not_active Expired - Lifetime
- 2004-03-23 US US10/807,766 patent/US7208509B2/en active Active
-
2005
- 2005-08-18 IL IL170343A patent/IL170343A/en active IP Right Grant
- 2005-09-15 NO NO20054264A patent/NO334095B1/no unknown
- 2005-09-21 CO CO05095661A patent/CO5601029A2/es not_active Application Discontinuation
- 2005-09-21 HR HR20050830A patent/HRP20050830A2/xx not_active Application Discontinuation
-
2007
- 2007-02-02 US US11/701,881 patent/US7348345B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0408767A (pt) | inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv | |
BRPI0407591A (pt) | inibidores de transcriptase reversa de não-nucleosìdeo | |
BRPI0408704A (pt) | benzil-piridazinonas como inibidores de transcriptase reversa | |
BRPI0208811B8 (pt) | derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos | |
BRPI0513858B8 (pt) | compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende | |
BR0312513A (pt) | Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos | |
BRPI0610030B8 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
BRPI0415759A (pt) | compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia | |
BRPI0512075A (pt) | composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença | |
BRPI0516972A (pt) | composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto | |
BR0209267A (pt) | Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf) | |
BRPI0215312B8 (pt) | composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto | |
BRPI0511982A (pt) | compostos antiviróticos heterocìclicos | |
BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
BR0210350A (pt) | Nucleosìdeos 4'-substituìdos | |
SE0402735D0 (sv) | Novel compounds | |
BR0317435A (pt) | Derivados de pirimidina para o tratamento do crescimento celular anormal | |
BR0314379A (pt) | Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase | |
BR0308212A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
BRPI0414948A (pt) | derivados de pirazolo-e-imidazo pirimidina | |
BRPI0518117A (pt) | uso de um derivado de piridotienopirimidina, composição farmacêutica, método para o tratamento de um sujeito que sofre de uma condição patológica ou doença susceptìvel de cura pela inibição da fosfodiesterase 4 e produto de combinação | |
BR0212069A (pt) | Agentes antidiabéticos orais | |
BRPI0315958B8 (pt) | composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
BR0210158A (pt) | Derivados de pirazol como inibidores da transcriptase reversa do hiv | |
BR0315320A (pt) | Composto ou sais farmaceuticamente aceitáveis dos mesmos, uso de um composto, composição farmacêutica, e, métodos para a terapia de dor em um animal de sangue quente e para produzir um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/03/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |